Results and Discussion

Traditionally, nuclear medicine procedures have had a place as sensitive screening procedures to help assess patients with potential primary or metastatic neoplasms. Most recent developments in immunology have resulted in several new radiopharmaceuticals which are either antibodies or active portions of antibodies (peptides) radiolabelled for imaging. This case demonstrates a specific use of antibody SPECT imaging for detecting/staging of prostate cancer.

Finally, ongoing developments in digital imaging have enhanced the accurate assessment of both physiology and anatomy by overlay or fusion of tomographic images from different modalities, typically CT or MR with nuclear SPECT or PET to precisely localize small focal accumulations of radiopharmaceutical in areas that may not even meet size criteria for CT or MR positivity, e.g. in lymph nodes.

Product Information

MIM (Medical Image Merge) is an image fusion program that was developed by Zalen, LLC and University Hospitals of Cleveland.